Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Musculoskeletal stiffness? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Musculoskeletal stiffness have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 0.1% of all adverse event reports for BLINATUMOMAB.

6
Reports of Musculoskeletal stiffness with BLINATUMOMAB
0.1%
of all BLINATUMOMAB reports
1
Deaths
2
Hospitalizations

How Dangerous Is Musculoskeletal stiffness From BLINATUMOMAB?

Of the 6 reports, 1 (16.7%) resulted in death, 2 (33.3%) required hospitalization.

Is Musculoskeletal stiffness Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Drug ineffective (345) Headache (335) Neutropenia (265) Febrile neutropenia (262)

What Other Drugs Cause Musculoskeletal stiffness?

ADALIMUMAB (10,762) METHOTREXATE (9,903) ETANERCEPT (9,744) TOFACITINIB (7,354) TOCILIZUMAB (6,346) RITUXIMAB (6,058) LEFLUNOMIDE (6,031) ABATACEPT (5,926) SECUKINUMAB (5,655) HYDROXYCHLOROQUINE (5,271)

Which BLINATUMOMAB Alternatives Have Lower Musculoskeletal stiffness Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Musculoskeletal stiffness Reports All Drugs Causing Musculoskeletal stiffness BLINATUMOMAB Demographics